Jill C Milne

Summary

Affiliation: Sirtris Pharmaceuticals
Country: USA

Publications

  1. ncbi The Sirtuin family: therapeutic targets to treat diseases of aging
    Jill C Milne
    Sirtris Pharmaceuticals, Inc, 790 Memorial Drive, Cambridge, MA 02139, USA
    Curr Opin Chem Biol 12:11-7. 2008
  2. ncbi Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators
    Chi B Vu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:1275-83. 2009
  3. ncbi Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
  4. ncbi Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
  5. ncbi Crystal structures of human SIRT3 displaying substrate-induced conformational changes
    Lei Jin
    Sirtris, a GSK Company, Cambridge, Massachusetts 02139, USA
    J Biol Chem 284:24394-405. 2009
  6. ncbi Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3
    Lei Jin
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    Protein Sci 18:514-25. 2009
  7. ncbi Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators
    Jean E Bemis
    Sirtris, a GSK Company, Cambridge, MA 01239, USA
    Bioorg Med Chem Lett 19:2350-3. 2009

Detail Information

Publications7

  1. ncbi The Sirtuin family: therapeutic targets to treat diseases of aging
    Jill C Milne
    Sirtris Pharmaceuticals, Inc, 790 Memorial Drive, Cambridge, MA 02139, USA
    Curr Opin Chem Biol 12:11-7. 2008
    ..Recent discoveries of small-molecule and protein modulators of Sirtuin deacetylation activity have provided enormous insight into the biological and molecular functions of Sirtuins and have validated their potential as therapeutics...
  2. ncbi Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators
    Chi B Vu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:1275-83. 2009
    ..The most potent analogue within this series, namely, compound 29, has demonstrated oral antidiabetic activity in the ob/ob mouse model, the diet-induced obesity (DIO) mouse model, and the Zucker fa/fa rat model...
  3. ncbi Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
    ....
  4. ncbi Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
    ..Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes...
  5. ncbi Crystal structures of human SIRT3 displaying substrate-induced conformational changes
    Lei Jin
    Sirtris, a GSK Company, Cambridge, Massachusetts 02139, USA
    J Biol Chem 284:24394-405. 2009
    ..These structures and biophysical studies provide key insight into the structural and functional relationship of the SIRT3 deacetylation activity...
  6. ncbi Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3
    Lei Jin
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    Protein Sci 18:514-25. 2009
    ..Thus, identification and characterization of the actual SIRT3 sequence should help resolve the debate about the nature of mouse SIRT3 and identify new mechanisms to modulate enzymatic activity...
  7. ncbi Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators
    Jean E Bemis
    Sirtris, a GSK Company, Cambridge, MA 01239, USA
    Bioorg Med Chem Lett 19:2350-3. 2009
    ..Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol...